following a full submission:
naproxen 500mg/esomeprazole 20mg (Vimovo®) is not recommended for use within NHS Scotland.
Indication under review: the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.
Studies have demonstrated that combined naproxen/esomeprazole was associated with a lower incidence of endoscopic gastric ulcers than NSAID alone and similar improvements in pain and functioning compared to a cyclo-oxygenase-2 selective inhibitor.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice141KB (PDF)
Medicine details
- Medicine name:
- naproxen + esomeprazole (Vimovo)
- SMC ID:
- 734/11
- Indication:
- For the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 November 2011